Study Title

novartis

PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Study Details

Description:

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

+41613241111

Government Study Link:

NCT06780670 - Click here to see study on

ClinicalTrials.gov

Drug Details

AAA817
Isotope(s):
    ACTINIUM-225
    Radioisotope: Ac-225
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 9.9 Days
    Decay Mode: ALPHA, GAMMA
    Energy: 5.8-8.4 MeV
    Range: 47-85 micrometers
    Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
    Status: Clinical Trials Only
  • ACTINIUM-225
Target(s):
  • PSMA

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Singapore

Novartis Investigative Site

Singapore

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468